Arnica Montana Root Berberis Vulgaris Root Bark Br

證據等級: L5

預測適應症: 0 個

---

目錄

1. Arnica Montana Root Berberis Vulgaris Root Bark Br
2. Multi-Component Homeopathic Formula: Repurposing Analysis Not Available
   1. One-Sentence Summary
   2. Quick Overview
   3. Why No Prediction Was Generated
   4. Clinical Trial Evidence
   5. Literature Evidence
   6. Safety Considerations
   7. Conclusion and Next Steps
   8. Disclaimer

---

## 藥師評估報告

Multi-Component Homeopathic Formula: Repurposing Analysis Not Available

One-Sentence Summary

This Evidence Pack contains a 13-component homeopathic combination formula (including Arnica Montana, Bryonia Alba, Rhus Toxicodendron, and others), which is not registered in the United States and has no original indication on record. The TxGNN model did not generate any repurposing predictions for this compound — likely because the multi-ingredient homeopathic structure cannot be mapped to a single DrugBank entry. Without a valid prediction target, evidence grading and a go/no-go recommendation cannot be issued at this time.

---

Quick Overview

Item	Content
Original Indication	Not available (no US license on record)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only; in this case, no prediction exists)
US Market Status	✗ Not marketed
Number of NDAs	0
Recommended Decision	Hold

---

Why No Prediction Was Generated

This compound is composed of 13 distinct botanical and mineral ingredients, all at homeopathic dilutions:

Arnica Montana Root · Berberis Vulgaris Root Bark · Bryonia Alba Whole · Causticum · Citrullus Colocynthis Fruit Pulp · Ferrosoferric Phosphate · Ledum Palustre Twig · Lycopodium Clavatum Spore · Ranunculus Bulbosus · Rhododendron Aureum Leaf · Solanum Dulcamara Top · Sulfur · Toxicodendron Pubescens Leaf

TxGNN is designed to operate on single-entity drugs mapped to a DrugBank node in the knowledge graph. This combination formula has no DrugBank ID (drugbank_id: null), which means:

1. It cannot be placed on the knowledge graph as a single node.
2. The graph traversal that generates disease scores has no starting point.
3. Without a prediction score, no downstream evidence evaluation (clinical trials, literature) is triggered.

Botanically, several components in this formula are traditionally associated with musculoskeletal and rheumatic complaints (Arnica, Bryonia, Rhus Tox, Rhododendron), but this observation is based on historical homeopathic use — not on a TxGNN model output — and therefore cannot constitute a repurposing recommendation.

---

Clinical Trial Evidence

Currently no related clinical trials registered.

---

Literature Evidence

Currently no related literature available.

---

Safety Considerations

Please refer to the package insert for safety information.

Note: All safety fields in this Evidence Pack — including key warnings, contraindications, and drug-drug interactions — returned [Data Gap] or not_found. No safety data can be reported at this time.

---

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline requires a single-drug DrugBank mapping to generate repurposing predictions; this 13-component homeopathic formula cannot be processed as a unified entity, leaving the analysis with zero prediction candidates and no evidence to evaluate.

To proceed, the following is needed:

• Decompose the formula: Evaluate each of the 13 components individually (e.g., Berberine from Berberis vulgaris, Arnica sesquiterpene lactones) against TxGNN to check if any single ingredient yields a clinically actionable repurposing signal.
• Obtain DrugBank mapping: If a surrogate active ingredient (e.g., Berberine, DB04115) can be identified as the primary pharmacological driver, re-run the pipeline using that DrugBank ID.
• Clarify original indication: Retrieve product label or TFDA registration records to establish what clinical condition this formula is claimed to address, which would anchor the “From → To” repurposing narrative.
• MOA documentation: Without mechanism-of-action data, even a mechanistic plausibility argument cannot be constructed. DrugBank or primary literature review for each ingredient is recommended.
• Regulatory status check: Confirm whether any individual components (e.g., Berberine, Colchicine-related alkaloids) hold independent regulatory approvals that could serve as comparators.

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---